poisar

Stocks · News reference

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover

Vandana Singh

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug portfolio.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ARGXFBRX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

    argenx announced that Phase 3 ALKIVIA study results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis will be presented as a late-breaking oral presentation at ACR Convergence 2026. The study met its primary endpoint, showing a 15.4-point greater improvement in Total Improvement Score versus placebo at Week 52 in the combined IMNM and DM population, with improvements observed as early as Week 4 and sustained through 52 weeks. The drug was well-tolerated with a consistent safety profile.

    ARGX
  5. SEC EDGAR

    8-K filing — Forte Biosciences, Inc. (FBRX)

    Filed: 2026-08-27 AccNo: 0001140361-26-034698 Size: 302 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

    FBRX
  6. Na

    argenx Completes Acquisition of Forte Biosciences, Inc.

    argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.

    ARGXFBRX